Twenty-plus years of SS-31 research is a lot of paper to wade through. This top SS-31 studies roundup does the sorting for you: the eight published papers that shaped the field most — the discovery-era foundations, the organ-system landmarks, the mechanism breakthroughs, and the aging studies that reframed what the compound might mean. Each entry in this top SS-31 studies list is summarized from the published record in research framing: what the investigators did, what they reported, and why the paper mattered. No hype, no human-use claims, no invented results — just the studies, in chronological order.
Research-use-only disclaimer: SS-31 (elamipretide) is a research compound. This top SS-31 studies article summarizes published papers; it contains no dosage information, no usage instructions, and no medical advice. Study findings describe experiments in the models used — they are not claims about human outcomes. All products on this site are sold strictly for laboratory research use.
How This Top SS-31 Studies List Was Built
“Top” needs a definition before the list means anything. These eight papers earned their places in this top SS-31 studies roundup by influence: they are the papers other SS-31 papers cite, the ones that opened new research directions, or the ones that settled a mechanism question the field had been circling. Foundational discovery work, first demonstrations in major organ systems, the cardiolipin mechanism papers, and the aging studies all qualify. Review articles are included only where they genuinely reframed the field. Full citations are given so every claim can be checked on PubMed.
2004–2007 · The foundation era
Discovery and first organ-system demonstrations: the peptide’s mitochondrial targeting is established, then tested in pancreatic islets and the heart.
2011–2013 · The expansion era
Kidney, hypertensive heart disease, and aging muscle join the map; the cardiolipin mechanism gets its landmark paper.
2014–present · The synthesis era
Mechanism reviews consolidate two decades of work while clinical trials of elamipretide advance in parallel — a story told in trial registries rather than single papers.
The Top SS-31 Studies, in Chronological Order
Zhao et al. — the discovery paper
Zhao K, Zhao G-M, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. “Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury.” Journal of Biological Chemistry 279(33):34682–34690.
What they did: the Szeto–Schiller team demonstrated that their small, cell-permeable peptides concentrated in the inner mitochondrial membrane — the first published evidence that this peptide class could be targeted to mitochondria at all.
Why it matters: every paper on this top SS-31 studies list descends from this one. It established the core premise — mitochondria-targeted, cell-permeable peptide antioxidants — that the entire field then spent two decades exploring. Without it, there is no SS-31 literature.
Thomas et al. — pancreatic islets and transplantation
Thomas DA, Stauffer C, Zhao K, Yang H, Sharma VK, Szeto HH, Suthanthiran M. “Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function.” Journal of the American Society of Nephrology 18(1):213–222.
What they did: the team applied SS-31 to pancreatic islet cells, reporting reduced cell death during isolation and improved function after transplantation in their model.
Why it matters: it was an early demonstration that mitochondrial protection could translate into a practical research outcome — better surviving cells for transplantation work — and it put SS-31 on the map beyond pure mechanism studies. A place on any top SS-31 studies list is earned by opening a new application domain, and this paper did exactly that.

Cho et al. — the heart enters the picture
Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, Hong MK. “Potent mitochondria-targeted peptides reduce myocardial infarction in rats.” Coronary Artery Disease 18(3):215–220.
What they did: in a rat model of myocardial infarction, the investigators reported that mitochondria-targeted peptides reduced infarct size.
Why it matters: the heart is the most energy-hungry organ in the body, making it the natural proving ground for a mitochondria-targeted compound. This study’s top SS-31 studies credential is priority: it was among the first to show the peptide’s promise in cardiac models, a thread that later ran all the way to human heart-failure trials.
Szeto et al. — ischemic kidney injury
Szeto HH, Liu S, Soong Y, Wu D, Darrah SF, Cheng FY, Zhao ZH, Ganger M, Tow CY, Seshan SV. “Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury.” Journal of the American Society of Nephrology 22:1041–1052.
What they did: in a model of kidney ischemia, the team reported that the peptide accelerated the recovery of ATP — the cell’s energy currency — and reduced kidney injury.
Why it matters: linking the compound directly to ATP recovery made the energy mechanism concrete rather than abstract. For a top SS-31 studies roundup, this paper is the clearest early statement of the “restore mitochondrial energetics” theme that defines the field.
Dai et al. — hypertensive cardiomyopathy
Dai DF, Chen T, Szeto H, Nieves-Cintron M, Kutyavin V, Santana LF, Rabinovitch PS. “Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy.” Journal of the American College of Cardiology 58:73–82.
What they did: the investigators studied the peptide in a model of hypertensive heart disease, reporting improvements in the cardiac measures they assessed.
Why it matters: publication in a major cardiology journal signaled that mitochondria-targeted peptides had arrived as a serious cardiovascular research topic — not a niche chemistry curiosity. Its top SS-31 studies standing comes from that legitimizing effect as much as from its findings.

Birk et al. — the cardiolipin mechanism landmark
Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH. “The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.” Journal of the American Society of Nephrology 24:1250–1261.
What they did: this is the paper that nailed down the mechanism: SS-31 interacts directly with cardiolipin in the inner mitochondrial membrane, stabilizing the membrane’s structure and the electron-transport machinery embedded in it.
Why it matters: arguably the single most cited mechanistic paper in the field, and the one this top SS-31 studies list would keep if it could keep only one from the 2010s. It moved the story from “antioxidant that goes to mitochondria” to “cardiolipin-binding compound that preserves membrane architecture” — a far more precise and more interesting claim, and the foundation for everything written about the mechanism since.
Siegel et al. — aging muscle
Siegel MA, Kruse SE, Percival JM, Goh J, White CL, Hopkins H, Kavanagh TJ, Szeto HH, Rabinovitch PS, Marcinek DJ. “Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.” Aging Cell 12(5):763–771.
What they did: in aged mice, the team reported rapid improvements in mitochondrial energetics and skeletal muscle performance after peptide treatment.
Why it matters: it connected SS-31 to the biology of aging itself — not a disease model but the aging process — and reported effects on a timescale (rapid) that surprised the field. Its top SS-31 studies place reflects that reframing: mitochondria-targeted peptides as aging research, not just disease research.
Szeto — the first-in-class synthesis
Szeto HH. “First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.” British Journal of Pharmacology 171:2029–2050.
What they did: Szeto consolidated a decade of work into a single comprehensive review, arguing the case for SS-31 as a first-in-class cardiolipin-protective compound.
Why it matters: reviews rarely make top SS-31 studies lists, but this one functions as the field’s state-of-the-union address — the paper newcomers are pointed to when they ask “where do I start.” It defined the vocabulary (cardiolipin protection, bioenergetic restoration) the rest of the literature still uses.

Top SS-31 Studies at a Glance
The summary table below compresses the top SS-31 studies roundup into a single reference — year, study, model system, and the contribution each paper is remembered for.
| Year | Study | Model / focus | Remembered for |
|---|---|---|---|
| 2004 | Zhao et al., J Biol Chem | Cell models | Discovery: mitochondria-targeted, cell-permeable peptides |
| 2007 | Thomas et al., JASN | Pancreatic islets | First practical application domain (transplantation) |
| 2007 | Cho et al., Coron Artery Dis | Rat myocardial infarction | Heart enters the research map |
| 2011 | Szeto et al., JASN | Kidney ischemia | ATP recovery made the mechanism concrete |
| 2011 | Dai et al., JACC | Hypertensive cardiomyopathy | Cardiology mainstreaming |
| 2013 | Birk et al., JASN | Ischemic mitochondria | Cardiolipin mechanism landmark |
| 2013 | Siegel et al., Aging Cell | Aged mice, muscle | Aging reframing; rapid effects |
| 2014 | Szeto, Br J Pharmacol | Review | Field-defining synthesis |
Reading these papers honestly: every study on this top SS-31 studies list was conducted in specific models — cells, rats, mice — with specific methods and specific endpoints. “Reduced infarct size in rats” is a finding about rats; it is not a finding about people. The discipline of reading animal-model papers without smuggling in human conclusions is the single most important skill this roundup can encourage. Later human-trial work lives in a different literature — registered trials on ClinicalTrials.gov — and should be read on its own terms.
What Came After: The Story Continues
No top SS-31 studies list is complete without noting where the trail leads. Later work extended the mechanism (including biophysical studies of how the peptide modulates membrane electrostatics), pushed deeper into aging biology, and — most consequentially — moved into human trials as elamipretide across mitochondrial myopathy, heart failure, macular degeneration, and Barth syndrome, culminating in FDA accelerated approval for Barth syndrome in September 2025. That clinical chapter belongs to trial registries and regulatory documents rather than single landmark papers, which is why this list stops where the preclinical story crystallizes. For orientation on the wider mitochondrial-peptide literature, see top Humanin studies roundup and the NIH resources on mitochondrial biology.
For researchers whose interests span multiple peptide classes, our Selank vs Semax research comparison applies the same literature-first discipline to a different corner of peptide research — and our research listings such as Semax 10mg and Selank 10mg show how laboratory reference materials are typically supplied. All products are sold strictly for laboratory research use.
Key Takeaways: Top SS-31 Studies
- This top SS-31 studies roundup spans 2004–2014: from Zhao et al.’s discovery paper through organ-system landmarks (islets, heart, kidney) to Birk et al.’s cardiolipin mechanism paper and Szeto’s field-defining 2014 synthesis.
- The arc of the literature runs discovery → application domains → mechanism precision → aging biology → human trials.
- The 2013 Birk et al. cardiolipin paper is the mechanistic center of gravity: it reframed SS-31 from generic antioxidant to cardiolipin-binding membrane stabilizer.
- Every finding belongs to its model — cells, rats, mice. Reading animal studies without importing human conclusions is the core discipline.
- The clinical chapter (elamipretide trials; September 2025 FDA accelerated approval for Barth syndrome) lives in trial registries, not in this papers list.
Research framing only — summaries describe published experiments, never usage or human outcomes.
Top SS-31 Studies: Final Notes
The top SS-31 studies tell a coherent twenty-year story: a targeted peptide class discovered in 2004, proven across organ systems through the late 2000s, mechanistically decoded in 2013, reframed around aging, and synthesized into a field identity in 2014 — before the clinical program carried the molecule to regulatory approval. Few research compounds have a paper trail this legible. For a new researcher, the eight papers above are the syllabus; everything else in the literature is commentary, extension, or application. Read them in order, keep the model systems straight, and the whole field clicks into place.
Top SS-31 Studies: Frequently Asked Questions
Quick answers to the questions researchers ask most about the SS-31 literature — all in research framing.
What is the most important SS-31 study?
Two papers share the crown in this top SS-31 studies roundup: Zhao et al. (2004, Journal of Biological Chemistry), which founded the field by demonstrating mitochondria-targeted, cell-permeable peptides; and Birk et al. (2013, JASN), which established the cardiolipin-binding mechanism. The first created the literature; the second explained it.
Which top SS-31 studies used animal models?
Most of them. Thomas et al. (2007) used islet models, Cho et al. (2007) used rats, Szeto et al. (2011) used kidney ischemia models, Dai et al. (2011) used hypertensive heart disease models, and Siegel et al. (2013) used aged mice. Findings describe those models — a central caveat of this entire top SS-31 studies list.
Do these studies prove SS-31 works in humans?
No. These are preclinical papers — cells and animal models. Human investigation happened separately, in registered clinical trials of elamipretide listed on ClinicalTrials.gov, culminating in FDA accelerated approval for Barth syndrome in September 2025. The papers and the trials are different literatures answering different questions.
Where can I read the full papers?
All eight are indexed on PubMed — search by first author and year (e.g., “Birk 2013 SS-31 cardiolipin”). Many are open access through PubMed Central. The longevity peptides research overview links the broader story.
Are there important SS-31 studies after 2014?
Yes — later work extended the biophysics of the mechanism, deepened the aging-biology findings, and moved into human trials. This top SS-31 studies list focuses on the papers that built the field’s foundation; the clinical chapter is best followed through trial registries and regulatory documents.
Is SS-31 the same as elamipretide in these papers?
Yes. SS-31 is the research name; elamipretide is the drug-development name used in clinical literature; MTP-131 and Bendavia are older code names. The molecule is the same across all the top SS-31 studies summarized here.

